{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:47:30Z","timestamp":1792162050510,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12917-1","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:09:02Z","timestamp":1792159742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-7080","authenticated-orcid":false,"given":"Ayman","family":"Alzu\u2019bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-2560","authenticated-orcid":false,"given":"Ejlal","family":"Abu-El-Rub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-124X","authenticated-orcid":false,"given":"Ghada","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Ghawanmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Almazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hmedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-429X","authenticated-orcid":false,"given":"Raed M.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"12917_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12905-025-03904-y","volume":"25","author":"B Jiang","year":"2025","unstructured":"Jiang B (2025) Analysis of global ovarian cancer disease burden and its changing trend from 1990 to 2021. BMC Womens Health 25(1):352","journal-title":"BMC Womens Health"},{"issue":"9","key":"12917_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L et al (2022) Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer 151(9):1535\u20131541","journal-title":"Int J Cancer"},{"issue":"1","key":"12917_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","volume":"30","author":"S Zafar","year":"2025","unstructured":"Zafar S, Hafeez A, Shah H, Mutiullah I, Ali A, Khan K et al (2025) Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives. Eur J Med Res 30(1):760","journal-title":"Eur J Med Res"},{"issue":"7","key":"12917_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/biom15071011","volume":"15","author":"IN Savas","year":"2025","unstructured":"Savas IN, Coskun A (2025) The future of tumor markers: advancing early malignancy detection through omics technologies, continuous monitoring, and personalized reference intervals. Biomolecules 15(7):1011","journal-title":"Biomolecules"},{"issue":"9","key":"12917_CR5","doi-asserted-by":"publisher","first-page":"oyaf242","DOI":"10.1093\/oncolo\/oyaf242","volume":"30","author":"E Shachar","year":"2025","unstructured":"Shachar E, Raz Y, Rotkop G, Levy B, Diner A, Laskov I et al (2025) Survivorship in advanced ovarian cancer: a prognostic model for overall survival and risk of recurrence. Oncologist 30(9):oyaf242","journal-title":"Oncologist"},{"issue":"11","key":"12917_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/cancers16112150","volume":"16","author":"KGJLTOI\u015aWPPM Sk\u00f3rzewska","year":"2024","unstructured":"Sk\u00f3rzewska KGJLTOI\u015aWPPM (2024) Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Cancers 16(11):2150","journal-title":"Cancers"},{"issue":"1","key":"12917_CR7","doi-asserted-by":"publisher","first-page":"oyae325","DOI":"10.1093\/oncolo\/oyae325","volume":"30","author":"R Rosso","year":"2025","unstructured":"Rosso R, Turinetto M, Borella F, Chopin N, Meeus P, Lain\u00e8 A et al (2025) Ovarian clear cell carcinoma: open questions on the management and treatment algorithm. Oncologist 30(1):oyae325","journal-title":"Oncologist"},{"issue":"2","key":"12917_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cancers14020416","volume":"14","author":"M K\u00f6bel","year":"2022","unstructured":"K\u00f6bel M, Kang EY (2022) The evolution of ovarian carcinoma subclassification. Cancers 14(2):416","journal-title":"Cancers"},{"issue":"1","key":"12917_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target therapy 5(1):28","journal-title":"Signal Transduct Target therapy"},{"issue":"4","key":"12917_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mco2.100","volume":"2","author":"M Liu","year":"2021","unstructured":"Liu M, Yang J, Xu B, Zhang X (2021) Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm 2(4):587\u2013617","journal-title":"MedComm"},{"issue":"6","key":"12917_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.surg.2014.02.006","volume":"155","author":"I Roy","year":"2014","unstructured":"Roy I, Evans DB, Dwinell MB (2014) Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery 155(6):961","journal-title":"Surgery"},{"issue":"2","key":"12917_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/ijms18020342","volume":"18","author":"MJ Stone","year":"2017","unstructured":"Stone MJ, Hayward JA, Huang C, Huma E, Sanchez Z (2017) Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci 18(2):342","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12917_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s44466-026-00038-0","volume":"2","author":"H He","year":"2026","unstructured":"He H, Yang P, Gao Y (2026) Chemokines and chemokine receptors: the key regulators of tumor microenvironment. Immun Inflamm 2(1):24","journal-title":"Immun Inflamm"},{"issue":"6","key":"12917_CR14","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/molecules30061380","volume":"30","author":"G Smaldone","year":"2025","unstructured":"Smaldone G, Di Matteo F, Castelluccio R, Napolitano V, Miranda MR, Manfra M et al (2025) Targeting the CXCR4\/CXCL12 axis in cancer therapy: analysis of recent advances in the development of potential anticancer agents. Molecules 30(6):1380","journal-title":"Molecules"},{"issue":"3","key":"12917_CR15","doi-asserted-by":"publisher","first-page":"e92629","DOI":"10.1371\/journal.pone.0092629","volume":"9","author":"C-F Liu","year":"2014","unstructured":"Liu C-F, Liu S-Y, Min X-Y, Ji Y-Y, Wang N, Liu D et al (2014) The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS ONE 9(3):e92629","journal-title":"PLoS ONE"},{"issue":"1","key":"12917_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40364-025-00778-y","volume":"13","author":"A Rueda","year":"2025","unstructured":"Rueda A, Serna N, Mangues R, Villaverde A, Unzueta U (2025) Targeting the chemokine receptor CXCR4 for cancer therapies. Biomark Res 13(1):68","journal-title":"Biomark Res"},{"issue":"10","key":"12917_CR17","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3390\/cancers12103071","volume":"12","author":"KA Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska KA, Katanaev VL (2020) The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis. Cancers 12(10):3071","journal-title":"Cancers"},{"issue":"17","key":"12917_CR18","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou W, Guo S, Liu M, Burow ME, Wang G (2019) Targeting CXCL12\/CXCR4 axis in tumor immunotherapy. Curr Med Chem 26(17):3026\u20133041","journal-title":"Curr Med Chem"},{"key":"12917_CR19","doi-asserted-by":"publisher","unstructured":"Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A (2013) Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis. OncoTargets therapy 1347\u20131361. https:\/\/doi.org\/10.2147\/ott.s36109","DOI":"10.2147\/ott.s36109"},{"issue":"45","key":"12917_CR20","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1038\/onc.2015.26","volume":"34","author":"E Pazarentzos","year":"2015","unstructured":"Pazarentzos E, Bivona TG (2015) Adaptive stress signaling in targeted cancer therapy resistance. Oncogene 34(45):5599\u20135606","journal-title":"Oncogene"},{"issue":"3","key":"12917_CR21","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"Z-NLQTQ-XTJNDWLZYPZ-S Chen","year":"2023","unstructured":"Chen Z-NLQTQ-XTJNDWLZYPZ-S (2023) Understanding and Targeting Resistance Mechanisms in Cancer. MedComm 4(3):e265","journal-title":"MedComm"},{"issue":"5","key":"12917_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider T, Pandey V, Banjare N, Gupta PN, Soni V (2020) Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep 72(5):1125\u20131151","journal-title":"Pharmacol Rep"},{"issue":"1","key":"12917_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12672-025-02725-7","volume":"16","author":"F Cheng","year":"2025","unstructured":"Cheng F, Shao F, Tian Y, Chen S (2025) Genomic and clinical insights into ovarian cancer: subtype-specific alterations and predictors of metastasis and relapse. Discover Oncol 16(1):907","journal-title":"Discover Oncol"},{"key":"12917_CR24","doi-asserted-by":"publisher","first-page":"117534","DOI":"10.1016\/j.lfs.2020.117534","volume":"249","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee K (2020) CXCL12\/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis. Life Sci 249:117534","journal-title":"Life Sci"},{"issue":"3","key":"12917_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/cas.15265","volume":"113","author":"X Wu","year":"2022","unstructured":"Wu X, Zhang H, Sui Z, Gao Y, Gong L, Chen C et al (2022) CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF-1\u03b1. Cancer Sci 113(3):926\u2013939","journal-title":"Cancer Sci"},{"key":"12917_CR26","doi-asserted-by":"publisher","first-page":"1683585","DOI":"10.3389\/fphar.2025.1683585","volume":"16","author":"PS Ramalingam","year":"2025","unstructured":"Ramalingam PS, Afzal M, Babu MA, Rekha MM, Sahoo S, Pandey SN et al (2025) CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent. Front Pharmacol 16:1683585","journal-title":"Front Pharmacol"},{"issue":"6","key":"12917_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4062\/biomolther.2024.137","volume":"32","author":"B Kim","year":"2024","unstructured":"Kim B, Park B (2024) Isoorientin suppresses invasion of breast and colon cancer cells by inhibition of CXC chemokine receptor 4 expression. Biomolecules Ther 32(6):759","journal-title":"Biomolecules Ther"},{"issue":"03","key":"12917_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cpt.2025.07.003","volume":"4","author":"AH Shaikat","year":"2026","unstructured":"Shaikat AH, Azad SAK, Tamim MAR, Ullah MS, Amin MN, Sabbir MK et al (2026) Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathogenesis Therapy 4(03):174\u2013191","journal-title":"Cancer Pathogenesis Therapy"},{"issue":"1","key":"12917_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","volume":"24","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N (2025) Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation. Mol Cancer 24(1):107","journal-title":"Mol Cancer"},{"issue":"22","key":"12917_CR30","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.3390\/cells11223698","volume":"11","author":"M Ra\u0161kov\u00e1","year":"2022","unstructured":"Ra\u0161kov\u00e1 M, Lacina L, Kej\u00edk Z, Venhauerov\u00e1 A, Skali\u010dkov\u00e1 M, Kol\u00e1\u0159 M et al (2022) The role of IL-6 in cancer cell invasiveness and metastasis\u2014overview and therapeutic opportunities. Cells 11(22):3698","journal-title":"Cells"},{"issue":"1","key":"12917_CR31","doi-asserted-by":"publisher","first-page":"14219","DOI":"10.1038\/s41598-017-14340-w","volume":"7","author":"A Das","year":"2017","unstructured":"Das A, Monteiro M, Barai A, Kumar S, Sen S (2017) MMP proteolytic activity regulates cancer invasiveness by modulating integrins. Sci Rep 7(1):14219","journal-title":"Sci Rep"},{"key":"12917_CR32","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.phrs.2020.105010","volume":"159","author":"J Wang","year":"2020","unstructured":"Wang J, Tannous BA, Poznansky MC, Chen H (2020) CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacol Res 159:105010","journal-title":"Pharmacol Res"},{"issue":"10","key":"12917_CR33","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","volume":"149","author":"S Bao","year":"2023","unstructured":"Bao S, Darvishi M, Amin H, Al-Haideri A, Patra MT, Kashikova I (2023) CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol 149(10):7945\u20137968","journal-title":"J Cancer Res Clin Oncol"},{"key":"12917_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Azad BB, Nimmagadda S (2014) The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31\u201382","journal-title":"Adv Cancer Res"},{"key":"12917_CR35","doi-asserted-by":"publisher","first-page":"1783222","DOI":"10.3389\/fimmu.2026.1783222","volume":"17","author":"S Tian","year":"2026","unstructured":"Tian S, Liu J, Yang X, Guo J (2026) The CXCL12-CXCR4 axis in colorectal cancer: immune regulation, metastatic progression, and therapeutic implications. Front Immunol 17:1783222","journal-title":"Front Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12917-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12917-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12917-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:09:03Z","timestamp":1792159743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12917-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12917"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12917-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1728"}}